Medical Conditions Associated with Central Sleep Apnea
Heart failure is the most common medical condition associated with central sleep apnea, followed by stroke, atrial fibrillation, renal failure, and opioid use. 1
Cardiovascular Disorders
Heart failure is the single most prevalent cause of CSA, typically presenting with Cheyne-Stokes respiration characterized by a long cycle length of 45-75 seconds, often accompanied by orthopnea and paroxysmal nocturnal dyspnea. 1 This association is so strong that patients with heart failure may require referral to sleep specialists for proper CSA management. 1
Atrial fibrillation causes CSA with a distinctly shorter cycle length (<45 seconds) compared to heart failure-associated CSA, providing a useful diagnostic clue on polysomnography. 1
Pulmonary hypertension is independently associated with CSA, even in the absence of heart failure. 1 This represents an important consideration when evaluating patients with unexplained CSA.
Neurological Disorders
Stroke disrupts brainstem respiratory control centers, leading to CSA through impaired ventilatory drive. 1 The American Academy of Sleep Medicine identifies neurological disorders as a primary etiology, with stroke patients showing a significantly elevated risk of CSA development. 1
In the pediatric population, neurological impairment is a notable risk factor, with affected infants presenting with concurrent central apneas. 1
Renal Disease
Renal failure leads to CSA through metabolic derangements that affect respiratory drive. 1 Chronic renal failure is frequently encountered as a secondary cause of CSA in clinical practice. 2
Medication-Induced CSA
Opioid analgesics cause CSA by directly inhibiting rhythm generation within the brainstem, resulting in a more abrupt onset temporally related to medication initiation or dose increase. 1 Sedative-hypnotics similarly exacerbate or precipitate CSA. 1
The American Geriatrics Society emphasizes obtaining a detailed medication list, particularly focusing on sedative-hypnotics and opiate analgesics, as these are common and reversible causes of CSA. 1
Genetic and Developmental Disorders
Prader-Willi syndrome (PWS) significantly increases CSA risk, with 43% of infants with PWS demonstrating CSA compared to only 5% of children aged 2-18 years. 3 Poor ventilatory control and scoliosis (affecting 15-86% of PWS patients) contribute to this elevated risk. 3
Polysomnography should be performed in infants with PWS at the time of diagnosis to rule out central apnea, with continued monitoring approximately every 6 months for those with central adrenal insufficiency. 3
Other Medical Conditions
Hypothyroidism frequently co-exists with CSA, particularly in older women, and can manifest with respiratory symptoms alongside psychiatric features. 4
High altitude exposure induces periodic breathing through alterations in ventilatory control. 1, 2
Obesity hypoventilation syndrome represents a form of hypercapnic CSA. 5
Treatment-Emergent CSA
Approximately 1% of patients starting CPAP therapy for obstructive sleep apnea develop treatment-emergent central sleep apnea, which typically resolves within 1-3 months without intervention. 1
Key Diagnostic Considerations
The cycle length on polysomnography helps distinguish etiologies: heart failure-associated CSA shows long cycle lengths (45-75 seconds), while atrial fibrillation, narcotics, pulmonary hypertension, renal failure, high altitude, and stroke are associated with shorter cycle lengths (<45 seconds). 1
Chemical control instability during light sleep (stages N1 and N2) is the primary mechanism underlying most CSA cases, when breathing operates under CO₂-dependent chemical control rather than wakefulness drive. 1
Critical Clinical Pitfall
Treatment of the underlying medical condition is the primary therapeutic approach for most forms of CSA. 1 However, avoid suppressing compensatory central sleep apnea in heart failure patients after optimal medical therapy, as it may represent a beneficial compensatory mechanism. 1